4Karthaus M, Cornely OA. Recent developments in the management of invasive fungal infections in patients with hematological malignancies[J].Ann Hematol, 2005,84 (2) : 207- 216.
5Anonymous. Empirical antifungal therapy in febrile granulocytopenic patients[J]. Am J Med,1989,86(6) :668-672.
6Ostrosky-Zeichner L,Marr KA,Rex JH,et al. Amphotericin B:time for a new "gold standard"[J]. Clin Inf Dis, 2003,37 (3) 415-425.
7Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus[J]. Clin Infect Dis, 2002,34 (1) : 7-14.
8Feinberg J. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage[J].AIDS Clinical Care,2003,15(11) :95-96.
9Groll AH, Attarbaschi A, Schuster FR, et al. Treatment with easpofungin in immunocompromised paediatric patients: a multicentre survey[ J ]. J Antimicrob Chemother, 2006,57 (3) 527-535.
10Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety,and tolerability of caspofungin in children and adolescents [J]. Antimicrob Agents Chemother, 2005,49 (1) : 4536-4545.
